Aim: To assess the role of genetic factors, other than the CAG repeat length, on the development of Huntington’s disease (HD) in an isolated Caucasian population in the south-west of Western Australia. Methods: 114 patients with symptomatic HD according to the Unified HD Rating Scale research criteria were examined along with 51 control patients. The length of the CAG repeat sequence in the IT15 gene and the adjacent CCG and Δ2642 polymorphisms were determined by polymerase chain reaction along with common genotypes of the angiotensin-converting enzyme (ACE) and apolipoprotein E (APOE) genes. Results: The CAG expansion was associated with age of onset and the development of neurological dysfunction. We found no effect of the expanded CCG allele on age of onset, neurological dysfunction or the size of the CAG expansion. We observed a twofold increase in the Δ2642 polymorphism and the risk of developing symptomatic HD which was not significant (OR 2.06; 95% CI 0.60–7.07). The presence of an APOE Ε4 allele was associated with an increased risk of HD which was not significant either (OR 1.04–1.73; 95% CI 0.10–10.68). ACE genotypes showed no association with risk factors for the disease. Conclusion: In our study of a geographically isolated Caucasian HD population in the south-west of Western Australia we have not observed that the expanded CCG allele, the Δ2642 polymorphism, the APOE Ε4 allele and ACE genotypes are associated with an increased risk for the development of symptomatic HD.

Keywords:
Huntington’s disease, Gene associations
1.
Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR: The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997;60:1202–1210.
2.
Duyao M, Ambrose C, Myers R, et al: Trinucleotide repeat length instability and age of onset in Huntington’s disease. Natl Genet 1993;4:387–392.
3.
Andrew SE, Goldberg YP, Kremer B, et al: The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Natl Genet 1993;4:398–403.
4.
Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR: A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet 2004;65:267–277.
5.
US-Venezuela Collaborative Research Project Team: Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci USA 2004;101:3498–3503.
6.
Rubinsztein DC, Leggo J, Chiano M, et al: Genotypes of the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington’s disease. Proc Natl Acad Sci USA 1997;94:3872–3876.
7.
MacDonald ME, Vonsattel JP, Shrinidhi J, et al: Evidence for the GluR6 gene associated with younger onset and Huntington’s disease. Neurology 1999;53:1164–1165.
8.
Vuillaume I, Vermersch P, Destée A, Petit H, Sablonnière B: Genetic polymorphisms adjacent to the CAG repeat influence clinical features at onset in Huntington’s disease. J Neurol Neurosurg Psychiatry 1998;64:758–762.
9.
Kehoe PG, Katzov H, Andreasen N, et al: Common variants of ACE contribute to variable age-at-onset of Alzheimer’s disease. Hum Genet 2004;114:478–483.
10.
Tian J, Shi J, Bailey K, et al: A polymorphism in the angiotensin-1-converting enzyme gene is associated with damage to cerebral cortical white matter in Alzheimer’s disease. Neurosci Lett 2004;354:103–106.
11.
Strittmatter WJ, Saunders AM, Schechel D, et al: Apolipoprotein E – High activity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1997–1981.
12.
Huntington Study Group: Unified Huntington’s disease rating scale: reliability and consistency. Mov Disord 1996;11:136–142.
13.
Beilby JP, Chin C, Porter I, Walpole I, Goldblatt J: Diagnosis of Huntington’s disease in a Western Australian population by analysis of an intragenic trinucleotide repeat expansion. Med J Aust 1994;161:356–360.
14.
Ambrose CM, Duyao MP, Barnes G, et al: Structure and expression of Huntington’s disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Genet 1994;20:27–38.
15.
Hung J, McQuillan BM, Nidorf M, Thompson P, Beilby JP: Angiotensin converting enzyme gene polymorphism and carotid wall thickening in a community population. Arterioscler Thromb Vasc Biol 1999;19:1969–1974.
16.
Beilby JP, Hunt CC, Palmer LJ, et al: Apolipoprotein E gene polymorphisms are associated with carotid plaque formation but not with intima-media wall thickening: results from the Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Stroke 2003;34:869–874.
17.
Rubinsztein DC, Barton DE, Davison BCC, et al: Analysis of the huntingtin gene reveals a trinucleotide length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington’s disease and CAG repeat number. Hum Mol Genet 1993;10:1713–1715.
18.
Andrew SE, Goldberg YP, Theilmann J, et al: A CCG polymorphism adjacent to the CAG repeat in Huntington’s disease gene: implications for diagnostic accuracy and predictive testing. Hum Mol Genet 1994;3:65–67.
19.
Barron LH, Rae A, Holloway S, et al: A single allele from the unstable CAG trinucleotide in the IT-15 cDNA shows almost complete disequilibrium with HD chromosomes in the Scottish population. Hum Mol Genet 1994;3:173–175.
20.
Novelletto A, Persichetti F, Sabbadind G, et al: Polymorphism analysis of the Huntington gene in Italian families affected with Huntington’s disease. Hum Mol Genet 1994;3:1129–1132.
21.
Sqitieri F, Andrew SE, Goldberg YP, et al: DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Hum Mol Genet 1994;3:2103–2114.
22.
Almqvist A, Spence N, Nichol K, et al: Ancestral differences in the distribution of the Δ2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington’s disease. Hum Mol Genet 1995;4:207–214.
23.
Goldblatt J, Bryer A: Huntington’s disease – Deterioration in clinical state during treatment with angiotensin converting enzyme inhibitor. Br Med J Clin Res Ed 1987;294:1659–1660.
24.
Monastero R, Caldarella R, Mannino M, et al: Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer’s disease. Neurosci Lett 2002;335:147–149.
25.
Lendon CL, Thaker U, Harris JM, et al: The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer’s disease. Neurosci Lett 2002;328:314–318.
26.
Carbonell J, Allen R, Kalsi G, et al: Variation in the DCPI gene, encoding the angiotensin converting enzyme ACE, is not associated with increased susceptibility to Alzheimer’s disease. Psychiatr Genet 2003;13:47–50.
27.
Camelo D, Arboleda G, Yunis JJ, et al: Angiotensin-converting enzyme and alpha2 microglobulin gene polymorphisms are not associated with Alzheimer’s disease in Colombian patients. J Neurol Sci 2004;218:47–51.
28.
Kalman J, Juhasz A, Majtenyi K, et al: Apolipoprotein E polymorphism in Pick’s disease and in Huntington’s disease. Neurobiol Aging 2000;21:555–558.
29.
Saft C, Andrich JE, Brune N, et al: Apolipoprotein E genotypes do not influence the age of onset of Huntington’s disease. J Neurol Neurosurg Psychiatry 2004;75:1692–1696.
30.
Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL: Age of onset in Huntington’s disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet 1999;36:108–111.
31.
Panas M, Avramopoulos D, Karadima G, Petersen MB, Vassilopoulos D: Apolipoprotein E and presenilin-1 genotypes in Huntington’s disease. J Neurol 1999;246:574–577.
32.
Ott J: Association of genetic loci – Replication or not, that is the question. Neurology 2004;63:955–958.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.